HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Silins, I. Articles by Dillner, J. Search for Related Content PubMed PubMed Citation Articles by Silins, I. Articles by Dillner, J. Agricola Articles by Silins, I. Articles by Dillner, J.

Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis

Elisabeth vall- Lundqvist²

Microbiology and Tumor Biology Center, Karolinska Institute, Box 280, S-171 77 Stockholm, Sweden¹
Department of Gynaecologic Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden²
University of Latvia, Riga, Latvia³
Department of Medical Microbiology, University of Mainz, Mainz, Germany⁴
Laboratory of Cellular Oncology, The National Cancer Institute, Bethesda, MD, USA⁵
Department of Infectious Disease Epidemiology, National Public Health Institute, Helsinki, Finland⁶

Author for correspondence: Joakim Dillner (at the Karolinska Institute). Fax +46 8 326 702. e-mail joakim.dillner{at}mtc.ki.se

Human papillomavirus (HPV) exists as more than 100 genotypes. It is not well-established whether the different HPV types interfere with infection or pathogenesis by each other. Possible interactions in cervical carcinogenesis between infection with the most common HPV types (6, 11, 16, 18 and 33) were studied in a seroepidemiological case- control study of 218 women with primary untreated cervical cancer and 219 healthy age-matched control women. As previously shown, HPV-16 seropositivity was associated with cervical cancer risk [odds ratio (OR), 2·39], but HPV-16 was not associated with cervical cancer risk among HPV-6 seropositive women (OR, 1·0). The relative excess risk due to interaction between HPV-6 and -16 was -2·35 (95% confidence interval, -0·04 to -4·65), indicating significant antagonism. The results suggest that infection with HPV-6 may interfere with HPV-16-associated cervical carcinogenesis.

This article has been cited by other articles:

				P. Naucler, H.-C. Chen, K. Persson, S.-L. You, C.-Y. Hsieh, C.-A. Sun, J. Dillner, and C.-J. Chen Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study J. Gen. Virol., March 1, 2007; 88(3): 814 - 822. [Abstract] [Full Text] [PDF]

				C. Masini, P. G. Fuchs, F. Gabrielli, S. Stark, F. Sera, M. Ploner, C. F. Melchi, G. Primavera, G. Pirchio, O. Picconi, et al. Evidence for the Association of Human Papillomavirus Infection and Cutaneous Squamous Cell Carcinoma in Immunocompetent Individuals Arch Dermatol, July 1, 2003; 139(7): 890 - 894. [Abstract] [Full Text] [PDF]

				M. Nakagawa, R. Viscidi, I. Deshmukh, M. D. Costa, J. M. Palefsky, S. Farhat, and A.-B. Moscicki Time Course of Humoral and Cell-Mediated Immune Responses to Human Papillomavirus Type 16 in Infected Women Clin. Vaccine Immunol., July 1, 2002; 9(4): 877 - 882. [Abstract] [Full Text] [PDF]

				I. Silins, I. Kallings, and J. Dillner Correlates of the Spread of Human Papillomavirus Infection Cancer Epidemiol. Biomarkers Prev., September 1, 2000; 9(9): 953 - 959. [Abstract] [Full Text]